PCI Pharma Services to acquire Sherpa Clinical Packaging

Leading clinical services provider Sherpa Clinical Packaging (Sherpa) has announced an agreement to be acquired by PCI Pharma Services (PCI). Sherpa, headquartered in San Diego, CA, provides clinical trial material management services for clinical studies phases I-IV, including packaging, labeling, distribution, storage and returns and destruction services. Sherpa’s state-of-the art facilities employ the latest cold chain technologies that include handling products requiring labeling and kitting at frozen and refrigerated conditions.

“Sherpa has always been committed to providing our customers with the best customer service and expertise in clinical supply management,” says Mark Paiz, President of Sherpa. “With this acquisition, our customers will now have access to PCI’s expanded clinical packaging services, extensive manufacturing of clinical trial materials, as well as global reach through U.S., European, and Asia Pacific depots to support their clinical studies.”

Headquartered in Philadelphia, PA, PCI provides its clients a global molecule-to-market service offering that spans contract development and manufacturing, including market-leading specialization in highly complex and potent drugs, clinical supply services and commercial packaging services. PCI’s clinical services include drug development and manufacturing, packaging and labeling, storage and logistical services, including support for Cold Chain and Ultra Cold Chain down to -196°C. The company is strategically and actively investing in the expansion of its global Clinical Services business and this marks its third acquisition in 12 months.

“We are extremely excited for what Sherpa brings to the PCI business,” notes Salim Haffar, CEO of PCI. “We have experienced considerable growth in our clinical business, and over the past 12 months made a number of key acquisitions to further expand our presence in key geographies including Ireland, Australia, and now California, along the way adding exciting new capabilities. Our #1 commitment to our clients is to provide the industry leading experience. This includes outstanding service, expansive capability, as well as the ability to support client studies around the world. Sherpa’s tremendous growth and reputation is clearly founded in their dedication to servicing their customers at the highest levels, which very much aligns to our core mission.”

Cantor Fitzgerald & Co. acted as exclusive financial advisor to Sherpa for this transaction and Snell & Wilmer LLP acted as legal counsel to Sherpa for this transaction.

About Sherpa Clinical Packaging
Sherpa Clinical Packaging provides clinical trial material management services for clinical studies phases I-IV, including packaging, labeling, distribution, storage and returns and destruction services. We manage trial materials for global studies using our cold-chain expertise and our global distribution network among our other offerings. Our agile managerial and operational systems are built to accommodate ever-changing clinical project requirements and fast turnaround times without sacrificing quality. Sherpa’s responsive team leverages its global expertise to identify and execute creative clinical supply solutions for all clients. 

About PCI Pharma Services
The global healthcare industry trusts PCI for the drug development solutions that increase their products’ speed to market and opportunities for commercial success. Only PCI brings the proven experience that comes with more than 50 successful product launches a year and over five decades in the healthcare business. Leading technology and continued investment enables us to address global development needs throughout the product life cycle — from Phase I clinical trials through commercialization and ongoing supply. Our clients view us as an extension of their business and a collaborative partner, with the shared goal of improving patients’ lives.

Read Similar Articles

0 Comments Write your comment

    1. Loading...